Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a look at why some wished-for gene therapies failed to make a splash when they came true and the words of ALS patients in the aftermath of another crushing setback.
Why hemophilia gene therapies haven’t taken off
After four decades and billions of dollars of research, science has finally produced gene therapies for hemophilia, the inherited disorder that stops blood from properly clotting. And yet patients, some of whom eagerly awaited one-time treatments, have been loath to try them.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect